You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.


KEDPLASMA USA Opens Two More Plasma Collection Centers, Re-Locates a Third; Ongoing Growth Benefits Rare Disease Patients

KEDPLASMA USA, one of the world’s leading collectors of high-quality human blood plasma, has added two additional plasma collection centers to its growing network – one in Sarasota, Florida, and another in Myrtle Beach, South Carolina. A third collection center has been re-located in Mobile, Alabama.

The new and re-located centers are part of a KEDPLASMA USA five-year plan to bring the number of plasma collection centers that it owns and operates to a total of over 30 by the year 2020. Plasma is a key component in a range of therapies used in treating certain rare diseases or conditions such as hemophilia, primary immune deficiency, rabies, prevention of Rh sensitization, and others. Therefore, as KEDPLASMA USA expands its operations, more patients across the U.S. may have access to the important therapies that, ultimately, are derived from the collected plasma.

With the two newest additions, KEDPLASMA USA now owns and operates 15 plasma collection centers nationwide.

“Donating plasma is one of the most gratifying things I can do,” said Tiara Fountain, a regular donor of plasma. “I know that, because of my donation, multiple people will benefit. The process usually takes less than two hours from start to finish, and really is pretty simple.”

“It is exciting to be growing so rapidly across the U.S. said Helen Nasser, KEDPLASMA USA Managing Director. “The need for safe, high quality plasma continues to escalate as more and more people with certain rare diseases are diagnosed and successfully treated, and as new indications for plasma are discovered. KEDPLASMA USA is certainly on the right track to continue helping more patients well into the future.”


KEDPLASMA LLC collects plasma for Kedrion Biopharma Inc., which is headquartered in Fort Lee, New Jersey and which is the U.S. subsidiary of Kedrion S.p.A. (Kedrion Biopharma) of Lucca, Italy. Kedrion Biopharma commercializes safe, effective, plasma-derived therapies that treat a range of rare and serious health conditions, including hemophilia, immunological and neurological conditions, and certain acute, life-threatening conditions requiring treatment in the critical care setting. In August, 2017, Kedrion Biopharma Inc. and Kamada, Ltd., a collaboration partner, received FDA approval to market KEDRAB™ [rabies immune globulin (Human)] in the United States. With the approval of KEDRAB, Kedrion Biopharma expanded its portfolio of immune globulin products, which includes RhoGAM™ and GAMMAKED™.

KEDPLASMA is also one of the largest suppliers of high titer rabies plasma in the world. All centers owned and operated by KEDPLASMA USA are regulated by the U.S. Food and Drug Administration and are monitored by the relevant European healthcare regulation authorities. 


For more information please contact: